Shots:

• Redx to receive $17M in early payment by the time of successful commencement of a P-I study- $360M as development- a regulatory and commercial milestone along with royalties on sales of the RXC006
• AstraZeneca to get an exclusive global license to further develop & commercialize RXC006 targeting fibrotic diseases including IPF
• Redx continues to progress its lead oncology asset- RXC004 (porcupine inhibitor) targeting Wnt-driven tumors- currently being evaluated in P-I/II clinical trial- and RXC007- the oral Rock 2 inhibitor targeting fibrosis where first in human studies are expected in 2021

­ Ref: AstraZeneca | Image: AstraZeneca